Three-Dimensional Collagen I Promotes Gemcitabine Resistance in Pancreatic Cancer through MT1-MMP–Mediated Expression of HMGA2

Surabhi Dangi-Garimella¹, Seth B. Krantz², Morgan R. Barron², Mario A. Shields¹, Michael J. Heiferman², Paul J. Grippo², David J. Bentrem²,³,⁴, and Hidayatullah G. Munshi¹,³,⁴

Abstract

One of the hallmarks of human pancreatic ductal adenocarcinoma (PDAC) is its pronounced type I collagen-rich fibrotic reaction. Although recent reports have shown that the fibrotic reaction can limit the efficacy of gemcitabine chemotherapy, the underlying mechanisms remain poorly understood. In this article, we show that the type I collagen allows PDAC cells to override checkpoint arrest induced by gemcitabine. Relative to cells grown on tissue culture plastic, PDAC cells grown in 3-dimensional collagen microenvironment have minimal Chk1 phosphorylation and continue to proliferate in the presence of gemcitabine. Collagen increases membrane type 1 matrix metalloproteinase (MT1-MMP)–dependent ERK1/2 phosphorylation to limit the effect of gemcitabine. Collagen also increases MT1-MMP–dependent high mobility group A2 (HMGA2) expression, a nonhistone DNA-binding nuclear protein involved in chromatin remodeling and gene transcription, to attenuate the effect of gemcitabine. Overexpression of MT1-MMP in the collagen microenvironment increases ERK1/2 phosphorylation and HMGA2 expression, and thereby further attenuates gemcitabine-induced checkpoint arrest. MT1-MMP also allows PDAC cells to continue to proliferate in the presence of gemcitabine in a xenograft mouse model. Clinically, human tumors with increased MT1-MMP show increased HMGA2 expression. Overall, our data show that collagen upregulation of MT1-MMP contributes to gemcitabine resistance in vitro and in a xenograft mouse model, and suggest that targeting MT1-MMP could be a novel approach to sensitize pancreatic tumors to gemcitabine. Cancer Res; 71(3); 1–9. ©2010 AACR.

Introduction

Very little progress has been made in the treatment of pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer-related deaths in the United States (1). Because pancreatic cancer causes minimal early signs or symptoms, most patients present with locally advanced or metastatic disease at the time of diagnosis (2). The primary treatment option for patients with advanced disease includes chemotherapy, with gemcitabine as the preferred therapy. Despite being the first line treatment for patients with PDAC, majority of the patients do not benefit from gemcitabine (3). Molecular targeted therapies have failed to show a clinically significant improvement over gemcitabine alone (4), raising an urgent need to understand the reasons for the poor response of PDAC tumors to current therapeutic agents.

Gemcitabine, a nucleoside analog that competes with cytidine during DNA replication, has been shown to activate cell cycle checkpoints that allow cells time for repair and determine whether to progress through the cell cycle or to undergo apoptosis. Gemcitabine activates Chk1 and Chk2 kinases, key effectors of the checkpoint response (5). Activation of Chk1 during DNA replication stalls cell cycle progression, prevents premature mitotic entry, and allows time to repair the damaged DNA. Cells resistant to arrest continue replicating despite the accumulated double-strand breaks, resulting in cells with mutations progressing through the cell cycle, causing genomic instability. Although Chk1 and Chk2 were initially thought to have specific roles, Chk2 may be redundant in checkpoint activation and may primarily modulate Chk1 responses (6).

Human pancreatic cancers are associated with an intense fibrotic reaction, the encasing tissue composed of interstitial extracellular matrix (ECM) and proliferating stromal cells. The fibrotic reaction was recently shown to limit the delivery and...
efficacy of gemcitabine in a mouse model of pancreatic cancer (7, 8). It also contributes to the malignant phenotype of PDAC (9), in part, by increasing expression of the proteinase membrane type 1 matrix metalloproteinase (MT1-MMP; ref. 10). PDAC is also associated with increased expression of high mobility group A2 (HMGA2): a nonhistone DNA-binding protein involved in chromatin remodeling and gene transcription (11). HMGA2 is increased in high-grade pancreatic tumors with lymph node metastases (12), and consistent with its role in pancreatic cancer invasion, HMGA2 is involved in maintaining Ras-induced epithelial-mesenchymal transition (EMT; ref.13). HMGA2 also modulates expression of genes that are important for cell proliferation, DNA repair, and apoptosis (14, 15).

In this article, we examine the mechanism by which collagen promotes gemcitabine resistance. We show that the 3-dimensional (3D) collagen microenvironment protects PDAC cells from gemcitabine-induced proliferation arrest and cell cycle arrest. The effect of collagen is mediated through increased MT1-MMP–dependent extracellular signal-regulated kinase (ERK1/2) phosphorylation and HMGA2 expression. Blocking MT1-MMP induction sensitizes pancreatic cancer cells in collagen to gemcitabine-induced checkpoint activation, whereas overexpressing MT1-MMP further attenuates gemcitabine-induced checkpoint arrest. Clinically, human tumors with increased MT1-MMP show increased HMGA2 expression. Overall, we show that collagen-mediated upregulation of MT1-MMP contributes to gemcitabine resistance in vitro and in a xenograft mouse model, and targeting MT1-MMP could be a novel approach to sensitize pancreatic tumors to gemcitabine.

Materials and Methods

Chemicals/reagents

MT1-MMP antibody was purchased from Abcam, ppERK1/2 and PARP antibodies from Cell Signaling, HMGA2 antibody from Biocheck Inc., and α-tubulin antibody from Santa Cruz Biotechnology. Secondary antibodies were purchased from Sigma. Type I collagen was purchased from BD Biosciences, Matrigel from R&D Systems, and MEK (MAP/ERK kinase) inhibitor U0126 from Cell Signaling. Gemcitabine was obtained from Eli Lilly. Nucleofector electroporation kit was purchased from Lonza and lipofectamine RNAiMax from Invitrogen. An HMGA2 siRNA and pre-miRs let-7a, let-7d, let-7g, and negative control #1 were purchased from Applied Biosystems. An siRNA for MT1-MMP targeted against nucleotides 228 to 248 was purchased from Invitrogen (16).

Cell culture

Panc1, CD18/HPAF-II, and AsPC1 cells were obtained from ATCC. Cells were maintained in Dulbecco’s modified Eagle’s medium containing 10% FBS and antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin). The cells were tested in December 2009 and June 2010 by STR profiling at the Johns Hopkins Genetic Resources Core Facility and showed a similar profile to that on the ATCC website.

Generation of PDAC cells inducibly expressing MT1-MMP

Full-length MT1-MMP and the ΔC mutant were subcloned into pRetroX-Tight-Pur vector (Clontech). Panc1 and CD18 cells inducibly expressing MT1-MMP were generated as previously described (17).

Transfection

Cells were transfected with siRNA against MT1-MMP, HMGA2, or control siRNA (50 nmoles), or the pre-miR to let-7 or pre-miR negative control (at 50 nmoles) using Nucleofector Kit R (Lonza), allowed to recover overnight and then plated either on plastic or in 3D collagen gels (2 mg/mL). Alternatively, cells were transfected using RNAiMax (Invitrogen) according to manufacturer’s instructions before plating into collagen.

Proliferation assay

Proliferation by 3H-thymidine incorporation was measured as previously described (18).

Quantitative real-time PCR analysis

Quantitative gene expression was performed for MT1-MMP, HMGA2, and GAPDH as previously published (17). Similarly, expression of let-7a/d/g and RNU48 was analyzed as previously published (19).

Immunoblotting

Immunoblotting was done as previously described (10). For cells grown in collagen, the matrix was first dissolved in collagenase (Worthington Biologicals) and then lysed as previously described (10).

Zymography

MT1-MMP activity analysis was done by SDS-PAGE gelatin zymography as described previously (17).

Subcutaneous tumor studies

Mice were treated in accordance with guidelines approved by the Northwestern University IACUC. Eight-week-old athymic nu/nu animals were injected subcutaneously with 10 × 10^6 tet-on Panc1-tet-V in the left flank whereas Panc1-tet-ΔC cells were injected into the right flank of the same animal. For CD18-tet-V and CD18-tet-ΔC, 5 × 10^3 cells were injected. Twenty-four hours later, doxycycline (200 mg/L) was added to the drinking water to induce protein expression. After 1 week, mice were intraperitoneally injected with 2 doses of gemcitabine (15 mg/kg) 2 days apart (20). Mice were then euthanized, and tumors processed for mRNA and histologic studies. The experiment to study the effect of inhibiting MT1-MMP expression in CD18 cells was conducted similarly. After maintaining the mice (n = 10) on doxycycline water for 2 weeks, 5 mice were switched to regular water for 1 week to inhibit MT1-MMP expression. Four mice in each group were then administered gemcitabine as described earlier. The tumor samples were stained for trichrome and hematoxylin and eosin (H&E), and immunostained for proliferating cell nuclear antigen (PCNA; 1:1,000, Santa Cruz Biotechnology). Images were taken...
using a Carl Zeiss Axiovert 200 imaging microscope at 80× (trichrome and H&E) or 320× (PCNA) magnification, maintaining similar settings between vector and MT1-MMP samples. The PCNA quantification for percentage of cells with nuclear staining was done using ImageJ software.

**Human pancreatic tumor samples**

Pancreatic tissue was obtained from patients with PDAC on an institutional review board (IRB)–approved protocol. Cancerous and adjacent normal tissue samples were dissected and processed for RNA extraction using Trizol. RNA quality was checked using Bioanalyzer-309 and samples with RNA Integrity Number (RIN) greater than 6 were used for gene expression studies.

**Statistical analysis**

All statistical analyses were done using GraphPad Instat 3 and Microsoft Excel (Student’s *t* test).

**Results**

**3D type I collagen protects PDAC cells from gemcitabine-induced cell cycle arrest**

Recently it was shown that the effect of gemcitabine was reduced by the fibrotic reaction in a mouse model of pancreatic cancer (7). To identify whether type I collagen, the most common ECM present in the fibrotic reaction, contributes to chemoresistance, we treated PDAC cells (Panc1, CD18, and AsPC1) grown on plastic or in 3D type I collagen gels (2 mg/mL) with gemcitabine (100 μmol/L) for 24 hours. The effect on proliferation was quantified by determining the ability of cells to incorporate 3H-thymidine and normalized to control untreated samples. *, *P* < 0.05 relative to cells grown on plastic; **, *P* < 0.01 relative to cells grown on plastic. B. PDAC cells were plated on tissue culture plastic or in 3D type I collagen gels for 24 hours. The effect on proliferation was quantified by 3H-thymidine incorporation. C. To examine the effect on checkpoint activation, cells were extracted out of collagen with collagenase treatment and the lysates immunoblotted for pS345Chk1 and α-tubulin. D and E, Panc1 cells were grown on plastic versus 3D collagen gels (D), or on 3D collagen versus in 3D collagen gels (E), treated with gemcitabine for 24 hours and immunoblotted for pS345Chk1 and α-tubulin.
microenvironment on checkpoint activation was unique to collagen or applicable to other matrices, we also examined the effect of 3D matrigel on checkpoint activation. As shown in Supplementary Figure S2, cells grown in 3D Matrigel showed similar response as in 3D collagen, indicating that the effect is mediated by the 3D microenvironment. Because collagen is the predominant ECM in human PDAC tumors, we conducted subsequent experiments in 3D collagen gels.

**HMGA2 contributes to gemcitabine resistance of PDAC cells in 3D collagen**

HMGA2 was recently shown to protect cancer cells from DNA damage-induced apoptosis (21). We therefore examined the role of HMGA2 in mediating the effect of collagen on gemcitabine-induced Chk1 phosphorylation. We initially found that Panc1 cells grown in collagen show increased expression of HMGA2 mRNA (Fig. 2A) and protein (Fig. 2B) relative to cells grown on plastic. To show that HMGA2 mediates the effect of collagen on gemcitabine-induced checkpoint arrest, Panc1 cells depleted of HMGA2 protein were grown in collagen in the presence or absence of gemcitabine. As shown in Figure 2C, knocking down HMGA2 sensitized Panc1 cells to gemcitabine-mediated cell cycle arrest as seen by the relative increase in Chk1 phosphorylation when compared with the control siRNA-transfected cells. Increased Chk1 phosphorylation in HMGA2-depleted cells was associated with a trend toward further reduction in proliferation in 3D collagen (Fig. 2D). Because the microRNA let-7 is a known inhibitor of HMGA2 (22), we examined the effect of collagen on let-7 levels and the contribution of let-7 to collagen-mediated attenuation of Chk1 phosphorylation. Panc1 cells in collagen show reduced levels of let-7 relative to cells on plastic (Supplementary Fig. S3A). Although pre-miR let-7 repressed HMGA2 expression (Supplementary Fig. S3B and C), it did not reverse the effect of collagen on gemcitabine-induced Chk1 phosphorylation (Supplementary Fig. S3D), indicating that let-7 and HMGA2 differentially affect Chk1 phosphorylation in collagen.

**The interplay between ERK1/2 and HMGA2 contributes to gemcitabine resistance of PDAC cells in collagen**

The MEK/ERK1/2 signaling pathway is known to be responsible for promoting survival signals, and blocking ERK1/2 phosphorylation with U0126 increases gemcitabine sensitivity (23, 24). Because Panc1 cells grown in collagen showed increased ERK1/2 phosphorylation compared with cells grown on plastic (Fig. 3A), we examined the effect of U0126 on collagen regulation of Chk1 phosphorylation. Treatment with U0126 inhibited collagen-induced ERK1/2 activation and HMGA2 expression (Fig. 3B), enhanced gemcitabine-induced Chk1 phosphorylation in Panc1 cells (Fig. 3C, top) and reduced proliferation (Fig. 3C, bottom). Interestingly, knocking down HMGA2 in Panc1 cells grown in collagen also decreased ERK1/2 phosphorylation (Fig. 3D), suggesting that a feedback loop exists between HMGA2 and ERK1/2 to help sustain ERK1/2 phosphorylation in the collagen microenvironment.

**MT1-MMP siRNA potentiates gemcitabine-induced checkpoint arrest and decreases HMGA2 and phosphorylated ERK1/2**

As we had previously shown that collagen induces MT1-MMP expression in PDAC cells (ref. 10; Fig. 4A), we examined the effect of MT1-MMP siRNA (Supplementary Fig. S4) on collagen regulation of Chk1 phosphorylation. Treatment with gemcitabine robustly induced pS345Chk1 in control siRNA-transfected cells plated on plastic, and collagen significantly attenuated the effect (Fig. 4B, top, compare lanes 2 and 6). Although MT1-MMP siRNA-transfected cells also showed robust pS345Chk1 on plastic, there was minimal attenuation of Chk1 phosphorylation in collagen (Fig. 4B, top, compare lanes 4 and 8). Similarly, MT1-MMP siRNA attenuated the effect of collagen on gemcitabine-induced pS345Chk1 in AsPC1 cells (Fig. 4B, bottom). These results show that collagen contributes to gemcitabine resistance of PDAC cells by increasing MT1-MMP. Knocking-down MT1-MMP also decreased collagen-induced ERK1/2 phosphorylation (Fig. 4C) and HMGA2 expression (Fig. 4D).

**MT1-MMP expression attenuates gemcitabine-induced checkpoint arrest by increasing HMGA2 and phosphorylated ERK1/2**

To further examine the role of MT1-MMP in mediating gemcitabine resistance in collagen, we generated Panc1 cells with inducible expression of wild-type or tailless (ΔC) MT1-MMP. Doxycycline treatment increased MT1-MMP expression (Supplementary Fig. S5A) and promoted MMP-2 activation, with the ΔC mutant showing a more pronounced effect...
As shown in Figure 5A, overexpression of MT1-MMP in collagen attenuated the effect of gemcitabine on Chk1 phosphorylation in Panc1 (top panel) and CD18 cells (bottom panel). Expression of both wild-type and tailless MT1-MMP protein also increased ERK1/2 phosphorylation and HMGA2 expression (Fig. 5B). To show that the effect of MT1-MMP on Chk1 phosphorylation was mediated by ERK1/2 and HMGA2 expression (Fig. 5B), Panc1 cells were grown in 3D collagen were treated with gemcitabine and cotreated with U0126 or DMSO for 24 hours. Lysates were immunoblotted for pS345Chk1, ppERK1/2, and α-tubulin (top). The effect of U0126 on proliferation was quantified by 3H-thymidine incorporation (bottom) and normalized to cells treated with DMSO alone. *, P < 0.05 relative to cells treated with DMSO alone.

MT1-MMP attenuates gemcitabine-induced proliferation arrest in vivo

To examine the role of MT1-MMP in attenuating the effect of gemcitabine in vivo, nude mice were subcutaneously injected with Panc1 or CD18 cells expressing vector in the left flank and tailless ΔC mutant of MT1-MMP in the right flank, allowed to develop tumors for a week, and then treated with gemcitabine. Tumors were excised and processed for MT1-MMP mRNA expression and stained with H&E and with trichrome to assess fibrosis, and for PCNA to examine proliferation. There was robust MT1-MMP expression in CD18-MT1-MMP and Panc1-MT1-MMP tumors relative to the corresponding control tumors (data not shown). Consistent with previous reports that MT1-MMP–expressing tumors show increased stromal reaction (17, 25), there was also increased stromal reaction in the MT1-MMP–expressing PDAC tumors (Fig. 6A). Additionally, there was suggestion of increased collagen in the MT1-MMP–expressing tumors as indicated by the increased blue staining in the trichrome images (Fig. 6B). Although there was no difference in the size of these tumors or their proliferation in the absence of gemcitabine treatment, MT1-MMP–overexpressing PDAC tumors displayed greater proliferation relative to control PDAC tumors following gemcitabine treatment (Fig. 6C and D). The gemcitabine treatment regimen used for these animal studies did not induce apoptosis; and given the short duration of these animal studies, no difference in tumor size was detected (data not shown).

We next examined whether switching off MT1-MMP in established tumors increases the sensitivity of PDAC cells to gemcitabine. CD18 cells expressing vector or ΔC were injected into nude mice and the mice were maintained on
doxycycline for 2 weeks to induce MT1-MMP. Thereafter, half of the mice were switched to regular water for an additional week to stop MT1-MMP induction before treatment with gemcitabine. As shown in Supplementary Figure S6, control mice maintained on doxycycline showed a 4- to 10-fold MT1-MMP induction in the CD18-DC tumors, whereas mice switched to regular water showed at most a 2-fold induction in MT1-MMP levels in the CD18-DC tumors. Significantly, switching off MT1-MMP expression in established tumors resulted in a statistically significant attenuation of proliferation (Fig. 6E and F). These experiments show that MT1-MMP can attenuate the effect of gemcitabine in the in vivo tumor microenvironment.

Discussion

The collagen-rich tumor microenvironment plays an essential role in cancer progression. Type I collagen not only promotes tumor migration and invasion of cancer cells, but also protects cancer cells against chemotherapy. Work done in lung cancer showed that collagen allows cells treated with chemotherapy to override checkpoints and continue through the cell cycle with damaged DNA (26). In our study, we delineate the mechanism by which collagen reduces the effectiveness of gemcitabine in pancreatic cancer. The effect of collagen on checkpoint arrest was seen primarily in the 3D collagen microenvironment and was not detected atop 3D gels, suggesting the importance of 3D tumor microenvironment in regulating cellular response. Cells in 3D Matrigel also showed attenuation of gemcitabine response, further showing the importance of 3D microenvironment. The differential effect of on collagen versus in collagen could be because of decreased penetration of gemcitabine into 3D collagen gels; however, it is now well established that cells respond differently to 2D surfaces versus 3D environments, and activate distinct pathways on 2D tissue culture plastic versus in 3D gels (27, 28).

We show that 3D collagen increases HMGA2 and thereby attenuates the effect of gemcitabine. Expression of HMGA1 has been shown to be a determinant of chemoresistance in pancreatic adenocarcinoma (29, 30), but a role for HMGA2 is yet to be established. Although HMGA2 can sensitize breast cancer and salivary epithelial cells to doxorubicin (31), it can also protect cancer cells against DNA damage-induced cytotoxicity. HMGA2 is part of the base end-join repair machinery that removes small damaged bases from the DNA, and has an apurinic/apyrimidinic lyase activity to protect against the effects of chemotherapy (21). HMGA2 contributes to genomic instability and tumor progression by inhibiting the DNA repair enzyme DNA-dependent protein kinase during the nonhomologous DNA end joining repair process (32). HMGA2 has been shown to maintain cancer stem cells in their undifferentiated state (33) and because stem cells are resistant to most cytotoxic chemotherapy, HMGA2 may contribute to chemotherapy resistance by modulating stem cell function.

We have found that collagen-induced HMGA2 induction involves ERK1/2 signaling, which agrees with a previous report showing that Raf-1–induced and phorbol 12-myristate 13-acetate–induced HMGA2 expression was blocked by the
MEK1/2 inhibitor PD98059 (34). ERK1/2 was also shown to upregulate HMGA2 in metastatic breast cancer cells (19), whereas inhibition of ERK1/2 decreased HMGA2 levels in PDAC cells (13). The MEK/ERK signaling pathway promotes chemotherapy resistance in a number of different cancers including multiple myeloma (35), hepatocellular carcinoma, (23) and pancreatic cancer (24). Inhibition of ERK1/2 signaling can also sensitize cancer cells to chemotherapy (36). Here we show that inhibiting ERK1/2 decreased collagen-induced HMGA2 induction, and sensitized cells to gemcitabine-induced checkpoint and proliferation arrest. Interestingly, we found that HMGA2 may function to sustain ERK1/2 phosphorylation, as downregulation of HMGA2 decreased ERK1/2 activation by collagen. These findings show that the interplay between HMGA2 and ERK1/2 contributes to attenuating the effect of gemcitabine in the collagen microenvironment.

HMGA2 is also regulated by the let-7 family of microRNAs, which can bind to the 3' UTR of HMGA2 and cause degradation of HMGA2 mRNA (22, 37). Although let-7 is a negative regulator of HMGA2 in PDAC cells, and we recently showed that MT1-MMP in turn inhibits let-7 in collagen (38), expression of pre-miR let-7 did not abrogate the effect of gemcitabine in the collagen microenvironment. Interestingly, a recent report showed that there was differential regulation of EMT and proliferation by HMGA2, and let-7 in pancreatic cancer cells (13). Knocking down HMGA2 with siRNA reversed the mesenchymal phenotype of pancreatic cancer cells and decreased proliferation; however, expression of let-7 did not affect EMT or proliferation even though HMGA2 levels were decreased (13).

The changes we observed in HMGA2-ERK1/2 signaling, and the downstream effect on gemcitabine sensitivity, were both mediated by collagen-induced MT1-MMP expression. Our studies show that knocking down MT1-MMP enhanced the effect of gemcitabine, whereas overexpressing MT1-MMP further attenuated the effect of gemcitabine in collagen. The effect of MT1-MMP on checkpoint arrest was mediated through HMGA2 and ERK1/2. Interestingly, the effect of MT1-MMP was only seen in the collagen microenvironment as modulation of MT1-MMP in cells on plastic had minimal effect on checkpoint arrest, suggesting that additional microenvironment-dependent signaling is required. It is now well established that 3D focal adhesions of cells are very different in molecular composition when compared with 2D focal adhesions (28). Significantly, MT1-MMP can increase the functionality of the collagen-binding α2β1 integrin in breast cancer cells (39). Moreover, integrin-linked kinase, which can interact with the cytoplasmic tail of β1 integrin, has been shown to contribute to gemcitabine resistance in pancreatic cancer cells (40). Thus, it is possible that MT1-MMP potentiates integrin signaling only in the 3D microenvironment to enhance gemcitabine resistance.

Clinically, it was recently shown that pancreatic cancer cells are not inherently resistant to gemcitabine, but the pro-
Figure 6. MT1-MMP attenuates gemcitabine-induced proliferation arrest in vivo. Nude mice \((n = 5)\) were injected with Panc1 or CD18 cells expressing vector in the left flank and \(\Delta C\) mutant of MT1-MMP in the right flank as detailed in Materials and Methods, and maintained on doxycycline water to induce MT1-MMP expression. Mice were injected with 2 doses of gemcitabine (15 mg/kg) intraperitoneally 2 days apart and the tumors excised and fixed in 10% formalin. Shown here are representative H&E (A), trichrome (B), and immunostaining for PCNA (C). D, quantitation of PCNA-positive cells for CD18 and Panc1 was done using ImageJ software. **, \(P < 0.01\) relative to cells expressing vector. E and F, nude mice \((n = 10)\) were subcutaneously injected with CD18 cells expressing vector in the left flank and \(\Delta C\) mutant of MT1-MMP in the right flank, and maintained on doxycycline water for 2 weeks to induce MT1-MMP expression. Five mice were then switched to regular water for 1 week to block MT1-MMP induction. Four animals in each group were then injected with 2 doses of gemcitabine (15 mg/kg) intraperitoneally, 2 days apart; the tumors were excised and analyzed for the percentage of proliferating cells using PCNA staining and ImageJ software. **, \(P < 0.01\) relative to cells expressing MT1-MMP.
been clearly shown that some MMPs possess tumor-inhibiting functions making it imperative to selectively target only the tumor-promoting MMPs \textit{in vivo} (45–48). Recently, a highly selective anti-MT1-MMP antibody was shown to inhibit growth, angiogenesis, and metastasis in a mouse model of breast cancer (49). Thus, evaluating this antibody in clinical trials may help address whether selective targeting of MT1-MMP blocks PDAC tumor growth and increases response to chemotherapy.

Overall, we show that the collagen-rich tumor microenvironment limits the effectiveness of gemcitabine through MT1-MMP–mediated HMGA2 expression as depicted by our model (Fig. 7). MT1-MMP is overexpressed in human PDAC tumors, particularly in areas of fibrosis. We now show that MT1-MMP expression is associated with increased HMGA2 expression in human PDAC tumors, suggesting that the pronounced fibrotic reaction may contribute to gemcitabine resistance through increased MT1-MMP-HMGA2 signaling. Given that very little progress has been made in the treatment of pancreatic cancer, targeting MT1-MMP could be a novel approach to sensitize pancreatic tumors to gemcitabine.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This research was supported by grant R01CA126888 (H.G. Munshi) from the NCI, and funding from the Elsa U. Pardee Foundation (H.G. Munshi) and the Rosenberg Family Fund (H.G. Munshi). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 24, 2010; revised November 2, 2010; accepted November 23, 2010; published OnlineFirst December 8, 2010.

Figure 7. Enhancement of gemcitabine resistance by MT1-MMP in PDAC. Our data show that PDAC cells in the collagen microenvironment express MT1-MMP, causing increased ERK1/2-dependent HMGA2 expression. This signaling pathway allows PDAC cells to resist gemcitabine-induced cell cycle arrest and proliferation arrest, both \textit{in vitro} and \textit{in vivo}.

References


Three-Dimensional Collagen I Promotes Gemcitabine Resistance in Pancreatic Cancer through MT1-MMP–Mediated Expression of HMGA2


Published OnlineFirst December 8, 2010.

Updated version Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-1855

Supplementary Material Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/12/08/0008-5472.CAN-10-1855.DC1

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/early/2011/01/12/0008-5472.CAN-10-1855. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.